Law360, New York (October 30, 2009, 1:23 PM ET) -- Merck & Co.’s proposed $41.1 billion acquisition of Schering-Plough Corp. has gained approval from U.S. antitrust regulators on the condition that both companies shed certain assets.
The Federal Trade Commission on Thursday gave the deal the green light as long as Merck sells its stake in Merial Ltd., an animal health joint venture with Paris-based Sanofi-Aventis, and Schering-Plough divests its assets associated with nausea drugs for humans. The companies have already taken steps to make the divestitures.
"The commission analyzed the likely impact of this proposed...
With Divestitures, FTC Allows Merck-Schering Deal
To view the full article, take a free trial now.
